Impact of macrophage differentiation on hematopoietic function enhancement by Shenzhu ErKang Syrup

Abstract

Shenzhu Erkang Syrup (SZEK) is a traditional Chinese medicine that improves spleen and stomach function, tonifying the Qi and activating the blood; however, its therapeutic effects in hematopoietic dysfunction and their underlying mechanism remain unexplored. In this study, mice were given cyclophosphamide (100 mg/kg) by intraperitoneal injections for three days to produce hematopoietic dysfunction model. We investigated the hematopoietic effect and mechanism of SZEK in mice with hematopoietic dysfunction via histopathological examination, flow cytometry, enzyme-linked immunosorbent assay, and Western blotting combined with intestinal flora and serum metabolomics analysis. In mice with hematopoietic dysfunction, SZEK (gavage, 0.3 mL/25 g) alleviated pathological damage to the bone marrow and spleen; increased the number of naïve cells (Lin − ), hematopoietic stem cells (Lin − Sca-1 + c-Kit + ), long-term self-renewing hematopoietic stem cells (Lin − Sca-1 + c-Kit + CD48 − CD150 + ), B lymphocytes (CD45 + CD19 + ), and macrophages (CD11b + F4/80 + ) in the bone marrow; and reduced inflammation. Preliminary intestinal flora and serum metabolome analyses indicated that the prohematopoietic mechanism of SZEK was associated with macrophage differentiation. Further validation revealed that SZEK promoted hematopoiesis by decreasing the number of M2 macrophages and inhibiting the secretion of negative hematopoietic regulatory factors in mice with hematopoietic dysfunction.